Search research articles
Contact Us
Filters
Showing results (121-130 of 147) with videos related to
Page
of 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M Moehler, A Maderer, P C Thuss-Patience, et al.
Actas Dermo-Sifiliograficas
|
July 5, 2015
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
J M Carrascosa, N Rivera, I Garcia-Doval, et al.
Circulation. Arrhythmia and Electrophysiology
|
January 27, 2023
Reduction in Junctophilin 2 Expression in Cardiac Nodal Tissue Results in Intracellular Calcium-Driven Increase in Nodal Cell Automaticity
Andrew P Landstrom, Qixin Yang, Bo Sun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 5, 2014
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry
C Medina, G Carretero, C Ferrandiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2018
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y-J Bang, E Yañez Ruiz, E Van Cutsem, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 2, 2014
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
G Carretero, C Ferrandiz, E Dauden, et al.
Leukemia
|
May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
A J Jakubowiak, D S Siegel, T Martin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 23, 2016
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
P Dávila-Seijo, E Dauden, G Carretero, et al.
ESMO Open
|
November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
J-P Metges, K Kato, J-M Sun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 10, 2017
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
I Belinchón, J M Ramos, G Carretero, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 147) with videos related to
Sort By:
Page
of 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M Moehler, A Maderer, P C Thuss-Patience, et al.
Actas Dermo-Sifiliograficas
|
July 5, 2015
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
J M Carrascosa, N Rivera, I Garcia-Doval, et al.
Circulation. Arrhythmia and Electrophysiology
|
January 27, 2023
Reduction in Junctophilin 2 Expression in Cardiac Nodal Tissue Results in Intracellular Calcium-Driven Increase in Nodal Cell Automaticity
Andrew P Landstrom, Qixin Yang, Bo Sun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 5, 2014
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry
C Medina, G Carretero, C Ferrandiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2018
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y-J Bang, E Yañez Ruiz, E Van Cutsem, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 2, 2014
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
G Carretero, C Ferrandiz, E Dauden, et al.
Leukemia
|
May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
A J Jakubowiak, D S Siegel, T Martin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 23, 2016
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
P Dávila-Seijo, E Dauden, G Carretero, et al.
ESMO Open
|
November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
J-P Metges, K Kato, J-M Sun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 10, 2017
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
I Belinchón, J M Ramos, G Carretero, et al.
Page
of 15